Clinical Trials on Resectable Pancreatic Ductal Adenocarcinoma

Total 2810 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
University Hospital, Rouen
Federation Francophone de Cancerologie Digestive; UNICANCER; Federation of Research... and other collaborators

Unknown

Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (PANACHE01)

Resectable Pancreatic Duct Adenocarcinoma

France
Jonsson Comprehensive Cancer Center
Arcus Biosciences, Inc.

Suspended

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; NovoCure Ltd.

Recruiting

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma

United States
Fundación de investigación HM
Syntax for Science, S.L

Active, not recruiting

Nalirinox Neo-pancreas RAS Mut ctDNA Study

Resectable Pancreatic Ductal Adenocarcinoma

Spain
Indiana University

Completed

A Phase II Study of Neoadjuvant FOLFIRINOX

Resectable Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
UMC Utrecht
Dutch Pancreatic Cancer Group (DPCG)

Enrolling by invitation

Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy (RADAR-PANC)

Resectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal Adenocarcinoma

Netherlands
Memorial Sloan Kettering Cancer Center

Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditions

United States
Lawson Health Research Institute
London Health Sciences Foundation

Not yet recruiting

Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma (ANSR-PDAC)

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Verastem, Inc.

Recruiting

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

United States
British Columbia Cancer Agency
BC Cancer Foundation; Pancreatic Cancer Canada

Unknown

The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001)

Resectable Pancreatic Ductal Adenocarcinoma

Canada
Roswell Park Cancer Institute

Not yet recruiting

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditions

United States
Case Comprehensive Cancer Center

Recruiting

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Resectable Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

United States
UNC Lineberger Comprehensive Cancer Center

Recruiting

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, Adult

United States
University of Utah
National Cancer Institute (NCI)

Active, not recruiting

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...

United States
HonorHealth Research Institute

Active, not recruiting

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Untreated Resectable Pancreatic Adenocarcinoma

United States
Massachusetts General Hospital

Terminated

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Resectable Pancreatic Cancer | Pancreatic Ductal Carcinoma

United States
National Cancer Center, Korea
Seoul National University Hospital

Not yet recruiting

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers (Dulastin)

Unresectable Pancreatic Cancer | Unresectable Biliary Tract Carcinoma | Unresectable Bile Duct Carcinoma
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; American Association for... and other collaborators

Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Erasmus Medical Center
Dutch Cancer Society; Dutch Pancreatic Cancer Group

Recruiting

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (PREOPANC-3)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Adenocarcinoma

Netherlands, Sweden, Norway
Zhejiang Cancer Hospital

Recruiting

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

HER2 Gene Mutation | Bile Duct Adenocarcinoma Non-Resectable

China
University Health Network, Toronto

Recruiting

FAZA PET/MRI Pancreas

Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Cancer | Pancreatic Adenocarcinoma Non-resectable

Canada
National Cancer Institute (NCI)

Recruiting

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
HonorHealth Research Institute

Active, not recruiting

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Unresectable Pancreatic Cancer | Neoadjuvant Pancreatic Cancer

United States
Medical College of Wisconsin
Cancer Research UK; Stand Up To Cancer; Lustgarten Foundation; HonorHealth Research... and other collaborators

Withdrawn

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Pancreatic Adenocarcinoma Resectable | Pancreatic Metastasis

United States
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
Hitendra Patel
Cancer Research UK; Stand Up To Cancer; Lustgarten Foundation; HonorHealth Research... and other collaborators

Withdrawn

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Pancreatic Adenocarcinoma Resectable | Pancreatic Metastasis

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

United States
Kimberly Perez, MD
Novartis

Terminated

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Borderline Resectable Pancreatic Adenocarcinoma

United States
HonorHealth Research Institute
Cancer Research UK; University of Arizona; Stand Up To Cancer; Lustgarten Foundation and other collaborators

Completed

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (AA NABPLAGEM)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Pancreatic Adenocarcinoma Resectable | Pancreas Metastases

United States
University Hospital Plymouth NHS Trust
University of Plymouth

Completed

Recurrence After Whipple's (RAW) Study

Pancreatic Cancer | Surgery | Bile Duct Cancer | Pancreatic Ductal Adenocarcinoma | Survivorship | Cholangiocarcinoma, Extrahepatic | Cancer Recurrence | Recurrent Cancer | Pancreatic Ductal Carcinoma | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampullary Cancer | Cholangiocarcinoma Resectable | Cancer... and other conditions

Spain, United Kingdom, Australia, Austria, Italy, Mexico, Sudan, Pakistan
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Sohag University

Completed

HER-2 Expression in Pancreatic Duct Adenocarcinoma

Pancreatic Adenocarcinoma
University of Oxford
National Institute for Health Research, United Kingdom; Imunon

Withdrawn

PanDox: Targeted Doxorubicin in Pancreatic Tumours (PanDox)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectable

United Kingdom
Weill Medical College of Cornell University

Unknown

EUS BD vs ERCP TP for Pancreatic Cancer (BILPAL)

Pancreatic Cancer | Pancreatic Adenocarcinoma | Periampullary Cancer | Biliary Tract Neoplasms | Unresectable Pancreatic Cancer | Biliary Duct Obstruction | Periampullary Carcinoma Non-Resectable

United States
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma

Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Resectable Pancreatic Ductal Adenocarcinoma | Localized Pancreatic Adenocarcinoma

United States
Georgetown University
ERYtech Pharma

Active, not recruiting

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Jean-Luc Van Laethem
Celgene Corporation

Completed

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer (NEOPAX-001)

Pancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally Advanced

Belgium
Candel Therapeutics, Inc.
Mayo Clinic

Active, not recruiting

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PaTK02)

Borderline Resectable Pancreatic Adenocarcinoma

United States, Mexico
IRCCS San Raffaele

Completed

EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)

Pancreatic Adenocarcinoma Non-resectable

Italy
First People's Hospital of Hangzhou

Completed

EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma Non-resectable

China
Medical University of South Carolina

Completed

A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Non-resectable

United States
Emory University
Ipsen; Taiho Oncology, Inc.

Recruiting

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Gastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditions

United States
Gilead Sciences

Terminated

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Previously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

United States
Weill Medical College of Cornell University

Terminated

RFA RCT for Pancreatic or Bile Duct Cancer (RFARCT)

Cholangiocarcinoma Non-resectable | Unresectable Pancreatic Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP

Pancreatic Ductal Adenocarcinoma | Gallbladder Carcinoma | Bile Duct Carcinoma

United States

Clinical Trials on Resectable Pancreatic Ductal Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations